# EDGAR Filing Document

**Accession Number:** 0001756390
**File Stem:** 0000000000-25-011834
**Filing Date:** 2025-12
**Character Count:** 2437
**Document Hash:** 8a98cefc79b8fb7375dd0b7657506c85
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-011834.hdr.sgml**: 20260225

**ACCESSION NUMBER**: 0000000000-25-011834

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251223

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ascend Wellness Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001756390
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 830602006
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-292300

**BUSINESS ADDRESS:**
- **STREET 1:** 44 WHIPPANY ROAD, SUITE 101
- **CITY:** MORRISTOWN
- **STATE:** NJ
- **ZIP:** 07960
- **BUSINESS PHONE:** (646) 661-7600

**MAIL ADDRESS:**
- **STREET 1:** 44 WHIPPANY ROAD, SUITE 101
- **CITY:** MORRISTOWN
- **STATE:** NJ
- **ZIP:** 07960

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ascend Wellness Holdings, Inc
- **DATE OF NAME CHANGE:** 20210420

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ascend Wellness Holdings, LLC
- **DATE OF NAME CHANGE:** 20181018
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001628280-25-058314

## Text-Extract

```

                                                           December 23, 2025

Roman Nemchenko
Chief Financial Officer
Ascend Wellness Holdings, Inc.
44 Whippany Road, Suite 101
Morristown, NJ 07960

       Re: Ascend Wellness Holdings, Inc.
           Registration Statement on Form S-3
           Filed December 19, 2025
           File No. 333-292300
Dear Roman Nemchenko:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Daniel Crawford at 202-551-7767 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   James Guttman, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._